Literature DB >> 28698204

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.

Sabrina Browning1, Karen Quillen1,2, J Mark Sloan1,2, Gheorghe Doros1,3, Shayna Sarosiek1,2, Vaishali Sanchorawala1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28698204     DOI： 10.1182/blood-2017-06-788729

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Blood Adv       Date:  2019-01-22

Review 2.  Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details.

Authors:  Vaishali Sanchorawala
Journal:  Blood Adv       Date:  2019-01-22

Review 3.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

4.  Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis.

Authors:  Marco Basset; Paolo Milani; Mario Nuvolone; Francesca Benigna; Lara Rodigari; Andrea Foli; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood Adv       Date:  2020-09-08

5.  Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.

Authors:  Andrew Staron; Eric J Burks; John C Lee; Shayna Sarosiek; J Mark Sloan; Vaishali Sanchorawala
Journal:  Blood Adv       Date:  2020-03-10

Review 6.  Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives.

Authors:  Shayna Sarosiek; Vaishali Sanchorawala
Journal:  J Blood Med       Date:  2019-10-23

7.  An eye-catching atypical illustration of the evaluation and management of AL amyloidosis secondary to myeloma.

Authors:  Shamis Khan; Sarah Premji; Quillan Huang; Gordana Verstovsek; Sita Bushan; Sarvari Venkata Yellapragada
Journal:  Clin Case Rep       Date:  2021-12-09

8.  Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.

Authors:  Abdullah S Al Saleh; Mohammad S Ebraheem; M Hasib Sidiqi; Angela Dispenzieri; Eli Muchtar; Francis K Buadi; Rahma Warsame; Martha Q Lacy; David Dingli; Wilson I Gonsalves; Taxiarchis V Kourelis; William J Hogan; Suzanne R Hayman; Prashant Kapoor; Shaji K Kumar; Morie A Gertz
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

9.  Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.

Authors:  Cameron S Fraser; Johan K E Spetz; Xingping Qin; Adam Presser; Jonathan Choiniere; Chendi Li; Stacey Yu; Frances Blevins; Aaron N Hata; Jeffrey W Miller; Gary A Bradshaw; Marian Kalocsay; Vaishali Sanchorawala; Shayna Sarosiek; Kristopher A Sarosiek
Journal:  Nat Commun       Date:  2022-10-02       Impact factor: 17.694

10.  Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Lawreen H Connors; Lisa M Mendelson; Tracy Joshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-08-04       Impact factor: 11.037
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.